• HAVN Life (HAVN) has secured a product listing with Loblaw (L), Canada’s largest grocery retailer
  • Loblaw will carry 6 of 11 HAVN Life natural health products nationally under store banners Atlantic Superstores, YIG (Your Independent Grocer), Dominion, Loblaws, Zehrs and Real Canadian Superstore
  • CEO Tim Moore spoke with Daniella Atkinson about the news
  • HAVN Life Sciences is a biotechnology company extracting psychedelic compounds to develop APIs, natural health products, and therapies to support brain health and immune function
  • HAVN Life Sciences (HAVN) is unchanged trading at $0.095 per share

HAVN Life (HAVN) has secured a product listing with Loblaw (L), Canada’s largest grocery retailer.

Loblaw will carry 6 of 11 HAVN Life natural health products nationally under store banners Atlantic Superstores, YIG (Your Independent Grocer), Dominion, Loblaws, Zehrs and Real Canadian Superstore.

Products are expected to hit shelves in November 2022.

The listing marks HAVN’s first partnership with a national retailer.

CEO Tim Moore spoke with Daniella Atkinson about the news and what it means for the company moving forward.

Fortinos, which approved HAVN for distribution in July 2022, has also approved the company’s Brain Evolve series of performance-enhancing supplements, which are also expected on shelves this November.

HAVN Life Sciences is a biotechnology company extracting psychedelic compounds to develop APIs, natural health products, and therapies to support brain health and immune function. Its formulations are non-GMO, vegan, bioavailable and naturally derived from plants and functional mushrooms.

HAVN Life Sciences (HAVN) is unchanged trading at $0.095 per share as of 1:39 pm ET.


More From The Market Online
labratory work

PharmaTher locks in FDA-assigned goal date of abbreviated NDA

PharmaTher Holdings (CSE:PHRM) locks in its U.S. FDA-assigned goal date of abbreviated new drug application for Oct. 29, 2024.

Optimi Health makes first international MDMA shipment

Optimi Health (CSE:OPTI) makes its first international shipment of MDMA to The Institute for Psychedelic Research at Tel Aviv University.

Oncolytics Biotech approved to expand pancreatic cancer program

Oncolytics Biotech (TSX:ONC), a cancer immunotherapy stock, receives ethics and German regulatory approvals for a new pancreatic cancer study.